Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2B randomized double-blind trial of MK-8189 in acute schizophrenia
jRCT2071200096Phase 2Completed
- Sponsor
- MSD
- Start
- Jun 2021
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of elpipodect in schizophrenia (5 arms), sponsored by MSD. Primary endpoints: Change from baseline in PANSS total score at Week 6 (MK-8189 24 mg vs placebo), Change from baseline in PANSS total score at Week 6 (MK-8189 16 mg vs placebo) and 3 more. Started Jun 2021; status: completed.
02
Drugs
elpipodect
03
Conditions
schizophrenia
Beyond the preview
Go deeper on jRCT2071200096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071200096.